Description
The Caov-3 cell line is a primary ovarian cancer cell line with epithelial morphology. These cells form tightly packed colonies in adherent culture. All-trans retinoic acid has been shown to suppress the growth of Caov-3 ovarian carcinoma cells in vitro. These cells express the NB/70K, CA-125, Ba-2, and Ca-1 tumor-associated antigens. The Caov-3 cells harbor a nonsense mutation in the p53 gene, and have multiple copies of the ovarian cancer oncogene PIK3CA. They are sensitive to vinblastine, cisplatin, and adriamycin. These cells fail to grow in soft agar but are tumorigenic when injected into immunocompromised mice.
Source
This cell line was established from the primary tumor of a 54-year-old Caucasian female with adenocarcinoma of the ovary.
Inventors
Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
Key References
- Buick RN et al. (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Research 45: 3668-3676 (PubMed ID: 4016745)
- Yaginuma Y et al. (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Research 52: 4196-4199 (PubMed ID: 1638534)
- Shayesteh L et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21: 99 - 102 (PubMed ID: 9916799)
Licensing Information
This cell line may be licensed nonexclusively for research or commercial purposes.
- Express License: For internal research purposes by a for-profit entity: 1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version. 2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
- Commercial License: Contact MSK’s Tangible Materials team at [email protected].
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected].